semaglutide oral drops for weight loss – BloomMD US FDA accepts Novo Nordisk's

Hypoglycemia is observed when GLP-1 receptor agonists are combined with insulin therapy, so clinicians and patients have to be attentive to reducing insulin dosages given the weight loss induced by GLP-1 receptor agonists

7 Future research should prioritize longitudinal studies to determine safety and effectiveness in diverse female populations

Ongoing clinical trials are planned, including evaluating tirzepatide as adjunctive therapy in individuals with a BMI over 27 who are already receiving infliximab or adalimumab treatment (NCT06774079)

Commercial patients represented 72.5% of GLP-1 initiators and Medicaid patients, 18.7%

In these patients, data are available from 8-point home glucose monitoring